Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03788902 |
| Other study ID # |
0017-13-SHA |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
February 1, 2014 |
| Est. completion date |
January 1, 2017 |
Study information
| Verified date |
December 2018 |
| Source |
Shalvata Mental Health Center |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Background: The current study aimed to explore the possible effect of stimulants on oxytocin
(OT), a neuropeptide found to regulate social behavior, as a mediator of the pro-social
effect of methylphenidate (MPH) in children with attention deficit hyperactivity disorder
(ADHD) compared to healthy controls (HCs). Methods: In a double-blind manner the
investigators compared the performance of 50 children with ADHD and 40 HCs in "theory of
mind" (ToM) tasks and examined the effect of a single dose of MPH/placebo on ToM and salivary
OT levels in children with ADHD at baseline and following an interpersonal interaction.
Description:
Attention deficit hyperactivity disorder (ADHD), a neurodevelopmental disorder affecting
approximately 7% of children and adolescents, is associated with considerable impairments in
social functioning. Children with ADHD, in comparison to healthy children, suffer from more
social rejection and problems in reciprocal relationships. Deficits in interpersonal
functioning in children with ADHD have been attributed in previous studies to, among other
things, impairments in theory of mind (ToM) - the ability to attribute mental states,
beliefs, and intentions to self and to others. For example, some studies have shown deficits
in the ability to recognize facial expressions among children with ADHD. Other studies have
found impairments in first- and second-order ToM tests. There is also evidence showing that
empathic functions in children with ADHD are impaired. However, small sample sizes, as well
as high percentages of comorbid disruptive disorders, served as limitations in these studies.
One's ToM ability depends on, among other things, the integrity of dopaminergic and
serotonergic systems, as well as on their interaction with other neurotransmitters and
neurohormones (e.g., acetylcholine, oxytocin).
Oxytocin (OT) is a neuropeptide found to accelerate the formation of social relationships,
the expression of behaviors of closeness, and the recognition of affect in the facial
expressions of others. Oxytocin has been hypothesized to raise the salience of social cues by
modulating attention-orienting responses to external contextual social cues. Its secretion
increases in response to interpersonal interactions. Studies found connections between blood
and saliva OT levels, OT receptor gene polymorphism, and the strength of social relationships
and behaviors in healthy individuals, as well as in patients suffering from mental disorders.
Oxytocin reciprocally interacts with dopaminergic neurons in the mesolimbic tract. Anatomical
and immonucytochemical studies have found that neuronal fibers and receptor binding-sites of
OT and dopamine are located in the same areas in the central nervous system (CNS), sometimes
in very close proximity to one another. Oxytocin-secreting cells in the hypothalamus carry
dopamine receptors. Indeed, patients with mental disorders related to dysregulation of
dopamine (e.g., autistic spectrum disorders, schizophrenia, depression) show changes in their
CNS and peripheral OT levels. Given the fact that injury of dopaminergic transporters and
receptors is a central component in the etiology of ADHD, it is also possible that OT plays a
role as a mediator of social deficits, and mainly in ToM impairment in children with ADHD.
To date, only a few studies have shown decreased OT levels in children with ADHD when
compared to healthy controls. These studies found a negative correlation between serum OT
levels and ADHD rating scale total scores, and aggression scores, and a positive correlation
between the serum OT level and empathy scores in patients with ADHD. However, in both
studies, only baseline OT levels were assessed; therefore, changes in OT levels following an
interpersonal interaction were not measured. This is an important point, as social abilities
are dynamic and interaction-related; the reactivity of the OT system to interpersonal
interaction is thus probably highly relevant to the understanding of social difficulties in
ADHD patients.
Stimulants reduce negative social interactions and improve social and behavioral functioning
in children with ADHD, and also improve empathy scores. In a previous study, the
investigators showed that a single dose of methylphenidate (MPH) improved the performance of
children with ADHD on ToM tests. To date, no study examined a possible effect of stimulants
on OT levels in children with ADHD. This is a pivotal issue in the understanding of the
neurobiological underpinnings of improvement in social cognition measures among children with
ADHD who are treated with stimulants, given that OT might have a role in mediating this
improvement.
In the current study the investigators hypothesized that dysfunction in the OT system may
account for the social difficulties of children suffering from ADHD and that the dynamics in
the OT system may explain the pro-social effect of stimulants on these children. Thus, the
objectives of the current study were 1) to compare ToM measures and salivary OT levels
between children with ADHD and healthy controls (HCs), and 2) to examine the effect of a
single dose of MPH on ToM and salivary OT levels in children with ADHD following an
interpersonal interaction.
Methods Subjects Fifty children aged 6-12 diagnosed with ADHD and 40 HCs were recruited.
Patients were recruited from the ADHD clinic and the outpatient clinic of the Shalvata Mental
Health Center, School of Medicine, Tel-Aviv University. The HCs subjects were recruited from
the community via the internet and social media.
ADHD was diagnosed by child and adolescent psychiatrists using the Diagnostic and Statistical
Manual of Mental Disorders, fourth or fifth edition (DSM-IV-TR and DSM-5). The investigators
excluded children with a past or current affective disorder, psychosis, substance abuse,
conduct disorder or any medical or neurological condition or medication-taking that might
affect the child's participation in the study. The investigators also excluded children who
had a first-degree relative with a major psychiatric diagnosis.
Inclusion criteria for the control group were the same as those of the ADHD group but with no
diagnosis of ADHD or a first-degree relative with ADHD.
Participants were reimbursed for their expanses in participation and received a small present
as appreciation. The IRB approved the study. Both parents of all participants signed a
consent form and the children gave their consent verbally.
Procedure Apart from the initial clinical assessment at the clinic, all assessments were
performed in the children's homes. Children with ADHD participated in two sessions: one
session an hour after taking a short-acting MPH (in an adjusted dosage of 0.3-0.5mg/kg) and
one session an hour after taking a placebo (PLC). Children routinely prescribed with MPH
treatment were asked not to take the medicine 48 hours before the examination, since the
clinical effect of the long-acting MPH is no longer than 12 hours. The study was
randomized-controlled, such that children were assigned to the sessions randomly in a
double-blind manner. Each session lasted about 60-90 minutes. In order to lessen a possible
learning effect of the computerized tasks (to be elaborated upon forthwith), the sessions
were performed at least two weeks apart. Control subjects participated in only one session
and did not take any medication.
Parents completed questionnaires regarding demographics and general information about the
child's academic and social functioning. In addition, parents completed the Swanson, Nolan
and Pelham Questionnaire-IV (SNAP-IV). This instrument contains subscales for inattention,
hyperactive/impulsive behavior, and oppositional behavior.
Parents also filled out the Strengths and Difficulties Questionnaire (SDQ), a screening
inventory composed of five distinct dimensions: conduct problems, emotional symptoms,
hyperactivity, peer problems, and pro-social behavior. Intelligence was measured using the
similarities subtest from the Wechsler Intelligence Scale for Children version IV (WISC-IV).
Self-reported anxiety was measured using the State-Trait Anxiety Inventory (STAI), a 40-item
questionnaire scored by a Likert scale. State anxiety represents a transient emotional status
that results from situational stress; trait anxiety represents a predisposition to react with
anxiety in stressful situations.
The investigators measured ToM performance using the ToM test, which test consists of
vignettes, stories, and drawings about which the child has to answer a number of questions.
Results are given on three subscales: ToM1 - precursors of ToM (i.e., recognition of
emotions); ToM2 - first manifestations of a real ToM (first-order belief, understanding of
false belief); and ToM3 - more advanced aspects of ToM (second-order belief, understanding of
humor). The second ToM task was the Faux Pas Recognition task (FPR), designed by Baron-Cohen
et al.. This task is designated to evaluate the ability of participants to recognize social
"faux pas" - social situations in which a speaker says something without understanding that
there might be a difference between his/her state of knowledge and that of the listener
("cognitive" ToM), and should recognize the potential emotional impact of a statement on the
listener ("affective" ToM). At each session, participants were given 10 short stories, five
of which contained faux pas situations to be identified. After hearing every story,
participants were asked ToM questions. The score consisted of the total number of all correct
identifications of a faux pas situation. The Hebrew version of the FPR was employed after
validation by a group of normative subjects.
Executive functions and attention were tested via the cognition module in the NIH Toolbox for
the Assessment of Neurological and Behavioral Function (NIH-TB). The investigators used the
Dimensional Change Card Sort Test (DCCS) and the Flanker Inhibitory Control and Attention
Test, which measure cognitive flexibility and inhibitory control, respectively.
Salivary OT levels were measured at three time points: at the beginning of each session
("T1"), 40 minutes after the administration of MPH/PLC ("T2"; only for the ADHD group), and
15 minutes after a "positive social interaction" in which the child and the parent were asked
to plan a "fun day" that would include both of them, and to talk about it for five minutes
("T3"). Participants were asked to avoid drinking and eating an hour before the test and to
avoid caffeine three hours before the test.
Saliva samples were collected by passive drool. In order to precipitate the mucus, samples
underwent three freeze-thaw cycles: freeze at -70°C and thaw at 4°C. After the forth cycle
the tubes were centrifuged twice at 1500 x g (4000 rpm) for 30 minutes. Supernatants were
collected and stored at -20°C until assayed. Determination of OT from saliva samples was
performed using a commercial OT ELISA kit (ENZO, NY, USA). Measurements were performed in
duplicate according to the manufacturer's instructions. The concentrations of samples were
calculated using MatLab-7 according to relevant standard curves. The intra-assay and
inter-assay coefficients of samples were 14.7 and 22.7 percent, respectively. The intra-assay
and inter-assay coefficients of controls were 4.9 and 13.2 percent, respectively.
